title: Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
abstract: We designed a multicenter Phase II trial to prospectively evaluate the efficacy and safety of the combination of rituximab with the DHAP regimen (dexamethasone, high-dose cytarabine, cisplatin) in patients who relapsed after or were resistant to a CHOP-like regimen. A total of 53 patients with relapsed or resistant aggressive B-cell NHL were analyzed. The overall response rate was 62.3 percent. With a median follow-up of 24.9 months, median overall and progression-free survivals were 8.5 and 6.7 months, respectively. Immunochemotherapy with rituximab and DHAP proved to be feasible and effective in this patient population.
authors.affiliation: Department of Internal Medicine I, University of Bonn, Germany. mey@uni-bonn.de
authors.forename: Ulrich J M
authors.initials: UJ
authors.lastname: Mey
authors.forename: Katjana S
authors.initials: KS
authors.lastname: Orlopp
authors.forename: Dimitri
authors.initials: D
authors.lastname: Flieger
authors.forename: John W
authors.initials: JW
authors.lastname: Strehl
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Ho
authors.forename: Manfred
authors.initials: M
authors.lastname: Hensel
authors.forename: Cordula
authors.initials: C
authors.lastname: Bopp
authors.forename: Marcus
authors.initials: M
authors.lastname: Gorschlüter
authors.forename: Martin
authors.initials: M
authors.lastname: Wilhelm
authors.forename: Josef
authors.initials: J
authors.lastname: Birkmann
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kaiser
authors.forename: Andreas
authors.initials: A
authors.lastname: Neubauer
authors.forename: Axel
authors.initials: A
authors.lastname: Florschütz
authors.forename: Christian
authors.initials: C
authors.lastname: Rabe
authors.forename: Corinna
authors.initials: C
authors.lastname: Hahn
authors.forename: Axel G
authors.initials: AG
authors.lastname: Glasmacher
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000473:pathology; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D000069283:Rituximab; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab; D003907:Dexamethasone; D002945:Cisplatin